Cancer cells with defective type I interferon responses (IFN-defective cancer cells)

Cancer cells with defective type I interferon (IFN) responses represent a common malignant phenotype where cells lose the ability to produce or respond to IFN-alpha and IFN-beta. This defect often arises from the selective loss, mutation, or epigenetic silencing of key signaling components such as the IFNAR receptors, JAK1/TYK2 kinases, STAT transcription factors, or cytosolic sensors like cGAS and STING (Zitvogel et al., 2015, Nature Reviews Immunology). While this impairment allows tumors to evade the growth-inhibitory and pro-apoptotic effects of interferons and escape immune surveillance, it creates a unique therapeutic vulnerability. Oncolytic viruses specifically exploit this lack of an antiviral state to selectively replicate within and lyse cancer cells while being neutralized by the intact IFN responses of healthy tissues (Lichty et al., 2014, Nature Reviews Cancer). Furthermore, modern immunotherapeutic strategies, including STING agonists, aim to bypass these defects to re-engage the innate immune system and convert immunologically "cold" tumors into "hot" tumors susceptible to checkpoint inhibition (Xia et al., 2016, Cell Reports).

Other names

Type I interferon-deficient tumor cellsIFN-non-responsive cancer cellsInterferon pathway-deficient malignant cellsIFN-alpha/beta signaling-defective tumors

Exploitation of impaired antiviral signaling for selective viral replication (oncolytic virotherapy) or pharmacological activation of alternative innate immune sensing pathways to restore anti-tumor immunity.